Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
284 studies found for:    regeneron
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
Condition: Osteoarthritis of the Knee or Hip
Interventions: Drug: Fasinumab;   Drug: Placebo
2 Completed Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: dupilumab;   Drug: placebo
3 Completed Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
Condition: Neovascular Age Related Macular Degeneration
Interventions: Drug: VEGF Trap;   Biological: VEGF Trap
4 Withdrawn A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Biological: REGN475;   Other: Placebo
5 Withdrawn Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury
Condition: Thermal Injury Pain
Interventions: Drug: R475;   Drug: Placebo
6 Withdrawn Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Conditions: Chronic Kidney Disease;   Anemia
Intervention: Drug: Rilonacept
7 Completed Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: VEGF Trap-Eye
8 Not yet recruiting A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
Conditions: Osteoarthritis, Knee;   Osteoarthritis, Hip
Interventions: Drug: Fasinumab;   Drug: Naproxen;   Drug: Fasinumab-matching placebo;   Drug: Naproxen-matching placebo
9 Not yet recruiting Study in Participants ≥12 Years of Age With Homozygous Familial Hypercholesterolemia (hoFH)
Condition: Homozygous Familial Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo
10 Recruiting Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
Condition: Healthy Volunteers
Interventions: Drug: Evinacumab;   Drug: Placebo
11 Not yet recruiting PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Condition: Carcinoma, Basal Cell
Intervention: Drug: REGN2810
12 Recruiting Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers
Condition: Healthy Volunteers
Interventions: Drug: REGN3918;   Drug: Placebo
13 Not yet recruiting Study of REGN3500 and Dupilumab in Patients With Asthma
Condition: Asthma, Allergic
Interventions: Drug: REGN3500;   Drug: Dupilumab;   Drug: Placebo;   Drug: Fluticasone propionate
14 Not yet recruiting Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Conditions: Carcinoma,Non-Small-Cell Lung;   Lung Carcinomas, Non-Small-Cell;   Non-small-cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: REGN2810
15 Recruiting Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
Conditions: Moderate-to-Severe Atopic Dermatitis;   Dermatitis, Dermatitis Atopic;   Eczema, Skin Diseases, Skin;   Diseases Genetic, Genetic;   Diseases Inborn, Skin;   Disease, Eczematous Skin;   Hypersensitivity, Immediate;   Hypersensitivity, Immune System Diseases;   Dermatitis, Atopic
Interventions: Drug: Dupilumab;   Drug: Placebo
16 Recruiting Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
Conditions: Atopic Disorders;   Eczema, Atopic
Interventions: Drug: Dupilumab;   Device: Auto-injector Device;   Device: Prefilled syringe
17 Recruiting Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Condition: Malignancies
Interventions: Drug: REGN3767;   Drug: REGN2810
18 Recruiting An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
Condition: Melanoma
Intervention: Drug: REGN2810
19 Recruiting Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
Conditions: Asthma;   Moderate Asthma
Interventions: Drug: REGN3500;   Drug: Placebo
20 Recruiting Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
Condition: Hypercholesterolemia
Interventions: Drug: Praluent (Alirocumab);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.